Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center

REFERENCES

1. 1.↵
   1. Mason JC

   . Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406–15.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Maksimowicz-McKinnon K,
   2. Hoffman GS

   . Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007;33:777–86,vi.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Arnaud L,
   2. Haroche J,
   3. Mathian A,
   4. Gorochov G,
   5. Amoura Z

   . Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev 2011;11:61–7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Murakami M,
   2. Nishimoto N

   . The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011;23:273–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Park MC,
   2. Lee SW,
   3. Park YB,
   4. Lee SK

   . Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology 2006;45:545–8.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Noris M,
   2. Daina E,
   3. Gamba S,
   4. Bonazzola S,
   5. Remuzzi G

   . Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55–60.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Seko Y,
   2. Sato O,
   3. Takagi A,
   4. Tada Y,
   5. Matsuo H,
   6. Yagita H,
   7. et al.

   Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation 1996;93:1788–90.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Maksimowicz-McKinnon K,
   2. Clark TM,
   3. Hoffman GS

   . Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000–9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kerr GS,
   2. Hallahan CW,
   3. Giordano J,
   4. Leavitt RY,
   5. Fauci AS,
   6. Rottem M,
   7. et al.

   Takayasu arteritis. Ann Intern Med 1994;120:919–29.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Freitas DS,
    2. Camargo CZ,
    3. Mariz HA,
    4. Arraes AE,
    5. de Souza AW

    . Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32:703–9.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Nishimoto N,
    2. Nakahara H,
    3. Yoshio-Hoshino N,
    4. Mima T

    . Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197–200.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Seitz M,
    2. Reichenbach S,
    3. Bonel HM,
    4. Adler S,
    5. Wermelinger F,
    6. Villiger PM

    . Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156.

    OpenUrlPubMed
13. 13.↵
    1. Salvarani C,
    2. Magnani L,
    3. Catanoso MG,
    4. Pipitone N,
    5. Versari A,
    6. Dardani L,
    7. et al.

    Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;1 Suppl 70:S90–3.

    OpenUrl
14. 14.↵
    1. Bredemeier M,
    2. Rocha CM,
    3. Barbosa MV,
    4. Pitrez EH

    . One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;1 Suppl 70:S98–100.

    OpenUrl
15. 15.↵
    1. Unizony S,
    2. Arias-Urdaneta L,
    3. Miloslavsky E,
    4. Arvikar S,
    5. Khosroshahi A,
    6. Keroack B,
    7. et al.

    Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720–9.

    OpenUrl
16. 16.↵
    1. Salvarani C,
    2. Magnani L,
    3. Catanoso M,
    4. Pipitone N,
    5. Versari A,
    6. Dardani L,
    7. et al.

    Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51:151–6.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Molloy ES,
    2. Langford CA,
    3. Clark TM,
    4. Gota CE,
    5. Hoffman GS

    . Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567–9.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Kerr GS

    . Takayasu’s arteritis. Rheum Dis Clin North Am 1995;21:1041–58.

    OpenUrlPubMed
19. 19.↵
    1. Xenitidis T,
    2. Horger M,
    3. Zeh G,
    4. Kanz L,
    5. Henes JC

    . Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology 2013;52:1729–31.

    OpenUrlFREE Full Text
20. 20.↵
    1. Dagna L,
    2. Salvo F,
    3. Tiraboschi M,
    4. Bozzolo EP,
    5. Franchini S,
    6. Doglioni C,
    7. et al.

    Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155:425–33.

    OpenUrlCrossRefPubMed